1
|
Otite FO, Patel SD, Anikpezie N, Hoffman H, Beutler T, Akano EO, Aneni E, Lamikanra O, Osondu C, Wee C, Burke D, Albright KC, Latorre JG, Mejico L, Khandelwal P, Chaturvedi S. Demographic Disparities in the Incidence, Clinical Characteristics, and Outcome of Posterior Reversible Encephalopathy Syndrome in the United States. Neurology 2023; 101:e1554-e1559. [PMID: 37487751 PMCID: PMC10585693 DOI: 10.1212/wnl.0000000000207604] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 05/16/2023] [Indexed: 07/26/2023] Open
Abstract
OBJECTIVES To estimate age-specific, sex-specific, and race-specific incidence of posterior reversible encephalopathy syndrome (PRES) in the United States. METHODS We conducted a retrospective cohort study using the State Inpatient Database of Florida (2016-2019), Maryland (2016-2019), and New York (2016-2018). All new cases of PRES in adults (18 years or older) were combined with Census data to compute incidence. We evaluated the generalizability of incident estimates to the entire country using the 2016-2019 National Readmissions Database (NRD). RESULTS Across the study period, there were 3,716 incident hospitalizations for PRES in the selected states. The age-standardized and sex-standardized incidence of PRES was 2.7 (95% CI 2.5-2.8) cases/100,000/y. Incidence in female patients was >2 times that of male patients (3.7 vs 1.6 cases/100,000/y, p < 0.001). Incidence increased with age in both sexes (p-trend <0.001). Similar demographic distribution of first hospitalization for PRES was also noted in the entire country using the NRD. Age-standardized and sex-standardized PRES incidence in Black patients (4.2/100,000/y) was significantly greater than in Non-Hispanic White (2.7/100,000/y) and Hispanic patients (1.2/100,000/y) (p < 0.001 for pairwise comparisons). DISCUSSION The incidence of PRES in the United States is approximately 3/100,000/y, but incidence in female patients is >2 times that of male patients. PRES incidence is higher in Black compared with non-Hispanic White and Hispanic patients.
Collapse
Affiliation(s)
- Fadar Oliver Otite
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore.
| | - Smit D Patel
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Nnabuchi Anikpezie
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Haydn Hoffman
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Timothy Beutler
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Emmanuel Oladele Akano
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Ehimen Aneni
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Oluwatomi Lamikanra
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Chukwuemeka Osondu
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Claribel Wee
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Devin Burke
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Karen C Albright
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Julius G Latorre
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Luis Mejico
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Priyank Khandelwal
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| | - Seemant Chaturvedi
- From the Department of Neurology (F.O.O., C.W., D.B., K.C.A., J.G.L., L.M.), SUNY Upstate Medical University, Syracuse, NY; Department of Neurosurgery (S.D.P.), University of Connecticut, Hartford; Department of Population Health (N.A.), University of Mississippi Medical Center, Jackson, MS; Department of Neurosurgery (H.H., T.B.), SUNY Upstate Medical University, Syracuse, NY; Molecular Neuropharmacological Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Section of Cardiovascular Medicine (E.A.), Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Department of Critical Care (O.L.), Springfield Clinic, IL; Baptist Health South Florida (C.O.), Miami; Departments of Neurology and Neurosurgery (P.K.), Rutgers University, Newark, NJ; and Department of Neurology (S.C.), University of Maryland, Baltimore
| |
Collapse
|
2
|
Kim Y, Koutsouras GW, Bourdages G, Beutler T. Insidious onset of spontaneous spinal epidural hematoma in immune thrombocytopenic purpura: a case-based review. Childs Nerv Syst 2023; 39:1903-1909. [PMID: 37126139 DOI: 10.1007/s00381-023-05963-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 04/16/2023] [Indexed: 05/02/2023]
Abstract
INTRODUCTION Spontaneous spinal epidural hematoma (SSEH) can result from various etiologies with a variable degree of neurological deficits. Here, we describe a rare case of SEH secondary to immune thrombocytopenic purpura (ITP) in a child and review the literature of SSEH caused by ITP. CASE REPORT A 9-year-old female who presented with rapid neurological decline, including bowel and bladder incontinence and paraparesis. A SSEH was observed extending from C2 to T6, causing a mass effect on the spinal cord. Her platelet count was only 7000/µL. Multidisciplinary care was established with neurosurgery, pediatric hematology, and pediatric surgery. The patient was managed emergently with splenectomy and surgical evacuation, with multilevel laminectomy and laminoplasty for evacuation of the hematoma. After a short course of rehabilitation, the patient regained all neurological function. CONCLUSION We report the first case of cervicothoracic SSEH secondary to ITP in a child managed with emergent splenectomy and surgical evacuation with multilevel lamoplasty. We also described the methods of timely diagnosis, urgent management, and overall prognosis of patients with this condition.
Collapse
Affiliation(s)
- YeonSoo Kim
- Department of Neurosurgery, SUNY Upstate University Hospital, Syracuse, NY, USA
| | - George W Koutsouras
- Department of Neurosurgery, SUNY Upstate University Hospital, Syracuse, NY, USA.
| | - George Bourdages
- Department of Neurosurgery, SUNY Upstate University Hospital, Syracuse, NY, USA
| | - Timothy Beutler
- Department of Neurosurgery, SUNY Upstate University Hospital, Syracuse, NY, USA
| |
Collapse
|
3
|
Hoffman H, Draytsel DY, Beutler T. Comparison of retroauricular and reverse question mark incisions for decompressive hemicraniectomy. World Neurosurg 2023:S1878-8750(23)00701-5. [PMID: 37236315 DOI: 10.1016/j.wneu.2023.05.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Accepted: 05/18/2023] [Indexed: 05/28/2023]
Abstract
BACKGROUND The retroauricular (RA) incision has several theoretical benefits compared to the reverse question mark (RQM) incision for decompressive hemicraniectomy (DHC), but limited data comparing the two exist. METHODS Consecutive patients who underwent DHC between 2016 - 2022 and survived ≥ 30 days at a single institution were included. The primary outcome was wound complication within 30 days (30dWC) requiring reoperation. Secondary outcomes included 90-day wound complication (90dWC), craniectomy size in anterior-posterior (AP) and superior-inferior dimensions, distance from the inferior craniectomy margin to the middle cranial fossa (MCF), estimated blood loss (EBL), and operative duration. Multivariate analyses were performed for each outcome. RESULTS A total of 110 patients (RA group: 27, RQM group: 83) were included. The incidence of 30dWC was 1.2% and 0 in the RQM and RA groups, respectively. The incidence of 90dWC was 2.4% and 3.7% in the RQM and RA groups, respectively. There was no difference in mean AP size (RQM: 15 cm, RA: 14.4 cm; p = 0.18), superior-inferior size (RQM: 11.8 cm, RA: 11.9 cm; p = 0.92), and distance from MCF (RQM: 15.4 mm, RA: 18 mm; p = 0.18). Mean EBL (RQM: 418 cc, RA: 314 cc; p = 0.36) and operative duration (RQM: 103 min, RA: 89 min; p = 0.14) were similar. There was no difference in cranioplasty wound complications, EBL, or operative duration. CONCLUSION Wound complications are comparable between the RQM and RA incisions. The RA incision does not compromise craniectomy size or temporal bone removal.
Collapse
Affiliation(s)
- Haydn Hoffman
- Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, NY, USA.
| | - Dan Y Draytsel
- Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, NY, USA
| | - Timothy Beutler
- Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, NY, USA
| |
Collapse
|
4
|
Xia C, Hoffman H, Anikpezie N, Philip K, Wee C, Choudhry R, Albright KC, Masoud H, Beutler T, Schmidt E, Gould G, Patel SD, Akano EO, Morris N, Chaturvedi S, Aneni E, Lamikanra O, Chin L, Latorre JG, Otite FO. Trends in the Incidence of Spontaneous Subarachnoid Hemorrhages in the United States, 2007-2017. Neurology 2023; 100:e123-e132. [PMID: 36289004 PMCID: PMC10499430 DOI: 10.1212/wnl.0000000000201340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 08/17/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVE To test the hypothesis that age-specific, sex-specific, and race-specific and ethnicity-specific incidence of nontraumatic subarachnoid hemorrhage (SAH) increased in the United States over the last decade. METHODS In this retrospective cohort study, validated International Classification of Diseases codes were used to identify all new cases of SAH (n = 39,475) in the State Inpatients Databases of New York and Florida (2007-2017). SAH counts were combined with Census data to calculate incidence. Joinpoint regression was used to compute the annual percentage change (APC) in incidence and to compare trends over time between demographic subgroups. RESULTS Across the study period, the average annual age-standardized/sex-standardized incidence of SAH in cases per 100,000 population was 11.4, but incidence was significantly higher in women (13.1) compared with that in men (9.6), p < 0.001. Incidence also increased with age in both sexes (men aged 20-44 years: 3.6; men aged 65 years or older: 22.0). Age-standardized and sex-standardized incidence was greater in Black patients (15.4) compared with that in non-Hispanic White (NHW) patients (9.9) and other races and ethnicities, p < 0.001. On joinpoint regression, incidence increased over time (APC 0.7%, p < 0.001), but most of this increase occurred in men aged 45-64 years (APC 1.1%, p = 0.006), men aged 65 years or older (APC 2.3%, p < 0.001), and women aged 65 years or older (APC 0.7%, p = 0.009). Incidence in women aged 20-44 years declined (APC -0.7%, p = 0.017), while those in other age/sex groups remained unchanged over time. Incidence increased in Black patients (APC 1.8%, p = 0.014), whereas that in Asian, Hispanic, and NHW patients did not change significantly over time. DISCUSSION Nontraumatic SAH incidence in the United States increased over the last decade predominantly in middle-aged men and elderly men and women. Incidence is disproportionately higher and increasing in Black patients, whereas that in other races and ethnicities did not change significantly over time.
Collapse
Affiliation(s)
- Christina Xia
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Haydn Hoffman
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Nnabuchi Anikpezie
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Karan Philip
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Claribel Wee
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Reema Choudhry
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Karen C Albright
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Hesham Masoud
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Timothy Beutler
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Elena Schmidt
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Grahame Gould
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Smit D Patel
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Emmanuel Oladele Akano
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Nicholas Morris
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Seemant Chaturvedi
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Ehimen Aneni
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Oluwatomi Lamikanra
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Lawrence Chin
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Julius G Latorre
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Fadar Oliver Otite
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL.
| |
Collapse
|
5
|
Zyck S, Du L, Gould G, Latorre JG, Beutler T, Bodman A, Krishnamurthy S. Scoping Review and Commentary on Prognostication for Patients with Intracerebral Hemorrhage with Advances in Surgical Techniques. Neurocrit Care 2021; 33:256-272. [PMID: 32270428 DOI: 10.1007/s12028-020-00962-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION The intracerebral hemorrhage (ICH) score provides an estimate of 30-day mortality for patients with intracerebral hemorrhage in order to guide research protocols and clinical decision making. Several variations of such scoring systems have attempted to optimize its prognostic value. More recently, minimally invasive surgical techniques are increasingly being used with promising results. As more patients become candidates for surgical intervention, there is a need to re-discuss the best methods for predicting outcomes with or without surgical intervention. METHODS We systematically performed a scoping review with a comprehensive literature search by two independent reviewers using the PubMed and Cochrane databases for articles pertaining to the "intracerebral hemorrhage score." Relevant articles were selected for analysis and discussion of potential modifications to account for increasing surgical indications. RESULTS A total of 64 articles were reviewed in depth and identified 37 clinical grading scales for prognostication of spontaneous intracerebral hemorrhage. The original ICH score remains the most widely used and validated. Various authors proposed modifications for improved prognostic accuracy, though no single scale showed consistent superiority. Most recently, scales to account for advances in surgical techniques have been developed but lack external validation. CONCLUSION We provide the most comprehensive review to date of prognostic grading scales for patients with intracerebral hemorrhage. Current prognostic tools for patients with intracerebral hemorrhage remain limited and may overestimate risk of a poor outcome. As minimally invasive surgical techniques are developed, prognostic scales should account for surgical candidacy and outcomes.
Collapse
Affiliation(s)
- Stephanie Zyck
- Department of Neurosurgery, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA.
| | - Lydia Du
- Northeast Ohio Medical University, Rootstown, OH, USA
| | - Grahame Gould
- Department of Neurosurgery, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA
| | | | - Timothy Beutler
- Department of Neurosurgery, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA
| | - Alexa Bodman
- Department of Neurosurgery, Emory University, Atlanta, GA, USA
| | - Satish Krishnamurthy
- Department of Neurosurgery, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA
| |
Collapse
|
6
|
Hoffman H, Abi-Aad K, Bunch KM, Beutler T, Otite FO, Chin LS. Outcomes associated with brain tissue oxygen monitoring in patients with severe traumatic brain injury undergoing intracranial pressure monitoring. J Neurosurg 2021; 135:1799-1806. [PMID: 34852324 DOI: 10.3171/2020.11.jns203739] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Accepted: 11/10/2020] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Brain tissue oxygen monitoring combined with intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury (sTBI) may confer better outcomes than ICP monitoring alone. The authors sought to investigate this using a national database. METHODS The National Trauma Data Bank from 2013 to 2017 was queried to identify patients with sTBI who had an external ventricular drain or intraparenchymal ICP monitor placed. Patients were stratified according to the placement of an intraparenchymal brain tissue oxygen tension (PbtO2) monitor, and a 2:1 propensity score matching pair was used to compare outcomes in patients with and those without PbtO2 monitoring. Sensitivity analyses were performed using the entire cohort, and each model was adjusted for age, sex, Glasgow Coma Scale score, Injury Severity Score, presence of hypotension, insurance, race, and hospital teaching status. The primary outcome of interest was in-hospital mortality, and secondary outcomes included ICU length of stay (LOS) and overall LOS. RESULTS A total of 3421 patients with sTBI who underwent ICP monitoring were identified. Of these, 155 (4.5%) patients had a PbtO2 monitor placed. Among the propensity score-matched patients, mortality occurred in 35.4% of patients without oxygen monitoring and 23.4% of patients with oxygen monitoring (OR 0.53, 95% CI 0.33-0.85; p = 0.007). The unfavorable discharge rates were 56.3% and 47.4%, respectively, in patients with and those without oxygen monitoring (OR 1.41, 95% CI 0.87-2.30; p = 0.168). There was no difference in overall LOS, but patients with PbtO2 monitoring had a significantly longer ICU LOS and duration of mechanical ventilation. In the sensitivity analysis, PbtO2 monitoring was associated with decreased odds of mortality (OR 0.56, 95% CI 0.37-0.84) but higher odds of unfavorable discharge (OR 1.59, 95% CI 1.06-2.40). CONCLUSIONS When combined with ICP monitoring, PbtO2 monitoring was associated with lower inpatient mortality for patients with sTBI. This supports the findings of the recent Brain Oxygen Optimization in Severe Traumatic Brain Injury phase 2 (BOOST 2) trial and highlights the importance of the ongoing BOOST3 trial.
Collapse
Affiliation(s)
| | | | | | - Timothy Beutler
- Departments of1Neurosurgery.,3Neurology, State University of New York Upstate Medical University, Syracuse, New York
| | - Fadar O Otite
- 3Neurology, State University of New York Upstate Medical University, Syracuse, New York
| | | |
Collapse
|
7
|
Ojukwu DI, Beutler T, Goulart CR, Galgano M. Bullet retrieval from the cauda equina after penetrating spinal injury: A case report and review of the literature. Surg Neurol Int 2021; 12:163. [PMID: 33948333 PMCID: PMC8088496 DOI: 10.25259/sni_238_2021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 03/24/2021] [Indexed: 11/16/2022] Open
Abstract
Background: When gunshot injuries occur to the spine, bullet fragments may be retained within the spinal canal. Indications for bullet removal include incomplete spinal cord injury, progressive loss of neurologic function including injury to the cauda equina, and dural leaks with impending risk of meningitis. Case Description: Here, we present a 34-year-old male with a missile penetrating spinal injury to the cauda equina. In addition to the computed tomography scan demonstrating retention of a bullet in the left L1/2 disc space, the scan suggested likely dural injury. The patient underwent a decompression/instrumented fusion with retrieval of the retained bullet fragment. A laminectomy was performed from T12 to L3, and at L1 and L2, a large traumatic durotomy was identified and repaired. The patient, unfortunately, continued to have bilateral lower extremity plegia with neurogenic bladder/bowel dysfunction at 1-year follow-up. Conclusion: We discuss the operative management and provide an intraoperative video showing the bullet extraction and dural closure.
Collapse
Affiliation(s)
- Disep I Ojukwu
- St. George's University, School of Medicine, Great River, New York, United States
| | - Timothy Beutler
- Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, New York, United States
| | - Carlos R Goulart
- Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, New York, United States
| | - Michael Galgano
- Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, New York, United States
| |
Collapse
|
8
|
Hoffman H, Verhave B, Jalal MS, Beutler T, Galgano MA, Chin LS. Comparison of Cortical Bone Trajectory Screw Placement Using the Midline Lumbar Fusion Technique to Traditional Pedicle Screws: A Case-Control Study. Int J Spine Surg 2019; 13:33-38. [PMID: 30805284 DOI: 10.14444/6005] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Background Cortical bone trajectory (CBT) screws are an alternative to traditional pedicle screws (PS) for lumbar fixation. The proposed benefits of CBT screws include decreased approach-related morbidity and greater cortical bone contact to prevent screw pullout. Relatively little data is published on this technique. Here, we compare the midline lumbar fusion (MIDLF) approach for CBT screw placement to transforaminal lumbar interbody fusion (TLIF) for traditional PS placement. Methods A prospectively maintained institutional database was retrospectively reviewed for all patients undergoing lumbar spinal fusion using CBT screws over the past 5 years. Controls were identified from the same database as patients undergoing lumbar spinal fusion with traditional PS placement and matched based on age, sex, and number of levels fused. Exclusion criteria included prior lumbar instrumentation. The electronic health record was retrospectively reviewed for demographic, perioperative, and postoperative data. Results A total of 23 patients who underwent CBT screw placement and 35 controls who received traditional PS were included in the study. The median follow-up time was 52.5 months. The CBT screw group had significantly less mean estimated blood loss than the PS group (186 mL versus 414 mL respectively; P = .008). Both groups experienced significant improvements in preoperative Oswestry Disability Index (ODI) and visual analog scale (VAS) scores for back and leg pain. However, there was no significant difference between the groups in regard to operative time and amount of improvement in VAS pain score or ODI. The CBT group was associated with a significantly shorter mean length of stay (LOS). There were 2 instances of screw pullout in each group. Conclusions The MIDLF approach with CBT screw placement is associated with less intraoperative blood loss and shorter LOS than traditional PS placement. There is no difference between the 2 techniques in regard to improvement in pain or disability.
Collapse
Affiliation(s)
- Haydn Hoffman
- State University of New York Upstate Department of Neurosurgery, Syracuse, New York
| | - Brendon Verhave
- State University of New York Upstate Department of Neurosurgery, Syracuse, New York
| | - Muhammad S Jalal
- State University of New York Upstate Department of Neurosurgery, Syracuse, New York
| | - Timothy Beutler
- State University of New York Upstate Department of Neurosurgery, Syracuse, New York
| | - Michael A Galgano
- State University of New York Upstate Department of Neurosurgery, Syracuse, New York
| | - Lawrence S Chin
- State University of New York Upstate Department of Neurosurgery, Syracuse, New York
| |
Collapse
|
9
|
Hoffman H, Ziechmann R, Beutler T, Verhave B, Chin LS. First-line management of chronic subdural hematoma with the subdural evacuating port system: Institutional experience and predictors of outcomes. J Clin Neurosci 2018; 50:221-225. [PMID: 29428265 DOI: 10.1016/j.jocn.2018.01.068] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2017] [Revised: 12/04/2017] [Accepted: 01/18/2018] [Indexed: 11/28/2022]
Abstract
Chronic subdural hematoma (cSDH) is a common condition that disproportionately affects older patients. Given the greater risks of general anesthesia in this population, interest has turned towards less invasive surgical approaches such as the subdural evacuating port system (SEPS; Medtronic, Inc., Minneapolis, MN). There is a relative dearth of information about the outcomes following this procedure. Here, we present our institution's experience with SEPS and analyze factors associated with the outcomes. Using a prospectively maintained institutional database, we retrospectively identified all patients who presented with cSDH and received first line therapy with SEPS. Pre- and post-operative clinical and radiographic data was obtained from the electronic health record. Outcomes included success or failure, Modified Rankin Scale (mRS) at discharge, length of stay (LOS), and discharge disposition. A total of 126 patients met the inclusion criteria (36 females and 90 males; mean age of 71.6 years). None of the pre-procedural clinical or radiographic variables were associated with the likelihood of a successful outcome. Increasing age was associated with non-routine hospital discharge (p = 0.003), and lower presenting GCS was associated with longer hospital stay (p = 0.005). Greater thickness of the cSDH was associated with a lower likelihood of having a favorable outcome (mRS ≥ 3; p = 0.003). SEPS is an effective first-line therapy for cSDH. Variables previously reported to limit the effectiveness of the technique (presence of septations, mixed density collections) were not associated with treatment failure.
Collapse
Affiliation(s)
- Haydn Hoffman
- Department of Neurosurgery, State University of New York Upstate, 750 E. Adams St., Syracuse, NY 13202, United States.
| | - Robert Ziechmann
- Department of Neurosurgery, State University of New York Upstate, 750 E. Adams St., Syracuse, NY 13202, United States
| | - Timothy Beutler
- Department of Neurosurgery, State University of New York Upstate, 750 E. Adams St., Syracuse, NY 13202, United States
| | - Brendon Verhave
- Department of Neurosurgery, State University of New York Upstate, 750 E. Adams St., Syracuse, NY 13202, United States
| | - Lawrence S Chin
- Department of Neurosurgery, State University of New York Upstate, 750 E. Adams St., Syracuse, NY 13202, United States
| |
Collapse
|
10
|
Abstract
We present a 69-year-old woman who presented with chronic headaches and was found to have a pituitary mass on MRI, which was biopsied and said to be lymphocytic hypophysitis. The woman was placed on prednisone and followed with routine eye examinations. Two years later, the lesion gradually increased in size and the woman developed a decrease in peripheral vision in the right eye. An MRI showed abutment of the right optic nerve by the mass. A repeat endoscopic transsphenoidal biopsy/resection of the pituitary lesion was performed. Histopathological analysis of the specimen was consistent with diagnosis of xanthomatous hypophysitis (XH). XH is an inflammatory disorder of the pituitary gland characterized by an infiltration of lipid-laden histiocytes, also known as xanthoma cells. The mass was biopsied and a diagnosis of lymphocytic hypophysitis was made. The woman reported improved visual acuity and peripheral vision postoperatively. One year after the second resection, her visual symptoms worsened. Repeat MRI revealed expansion of the residual pituitary tissue. She was referred to the radiation oncology department for external beam radiation therapy and was placed on a maintenance dose of steroids. Since undergoing radiation therapy, her vision has improved slightly and her 3month MRI revealed stable lesion size. This woman illustrates a rare pituitary pathology presented with a literature review of published patients describing xanthomatous hypophysitis. A discussion of the clinical presentation, epidemiology, etiology, diagnosis, histology and treatment is provided.
Collapse
Affiliation(s)
- Bishoy Hanna
- Department of Surgery, Staten Island University Hospital, 28 Arvin Road, Old Bridge, NJ 08857, USA.
| | - Yan M Li
- Department of Neurosurgery, State University of New York, Upstate Medical University, Syracuse, NY, USA
| | - Timothy Beutler
- Department of Neurosurgery, State University of New York, Upstate Medical University, Syracuse, NY, USA
| | - Parul Goyal
- Department of Otolaryngology, State University of New York, Upstate Medical University, Syracuse, NY, USA
| | - Walter A Hall
- Department of Neurosurgery, State University of New York, Upstate Medical University, Syracuse, NY, USA
| |
Collapse
|
11
|
Saha S, Patel M, Bilchik A, Beutler T, Zuber M, Bembenek A, Kitagawa Y, Duben J, Codignola C, Cserni G. Validation of sentinel lymph node (SLN) mapping (M) in colon cancer (Cca) over three continents: An international experience. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4047 Background: Lymph node (LN) status is the most important prognostic factor in colon cancer (Cca). In various trials, the average nodal positivity of conventional surgery in Cca is about 33%. Ultrastaging of SLNs results in higher and more accurate nodal staging of patients (pts) with Cca. However, some recent publications of SLNM in Cca have shown variable results with differing conclusions. Hence, prospective data from 3 continents were analyzed to study the international experience of SLNM in Cca. Methods: Only centers with experience of 40 or more cases of SLNM in Cca were included in the study. SLNM was performed by peri-tumoral injections of 1–3 ml of 1% lymphazurin. First 1–4 blue nodes marked as SLNs were ultrastaged by multilevel microsections for H&E and IHC. Data for calculating the success rate, accuracy, skip metastases (mets), sensitivity, negative predictive value; nodal positivity and upstaging were collected from each center. Results: Our study included a total of 1,216 Cca pts from 9 centers over 3 continents. SLNM was successful in 92.9% pts ( Table 1 ). The average number of LN/pt was 18.5 and the average number of SLN/pt was 2.7. The overall sensitivity, accuracy rate and negative predictive value were 78.3%, 89.4% and 82.8% respectively. Nodal mets were found in 52.9% pts. Of these, SLNs were the exclusive site for mets in 30.1% pts while 18.3% pts were upstaged by SLNM. Skip mets were seen in 21.7% pts (range 9.5% - 44.1%). Conclusions: SLNM is highly successful in Cca when performed by experienced surgeons worldwide. Nodal positivity was found to be much higher in pts undergoing SLNM compared to conventional surgery. Upstaged pts may benefit from adjuvant chemotherapy. Though the variation of skip mets was wide, the clinical impact of skip mets in Cca is negligible compared to that in melanoma and breast cancer, since all pts undergo standard lymphadenectomy and all node positive pts (true +ve & skip mets) are usually treated with adjuvant chemotherapy. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Saha
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - M. Patel
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - A. Bilchik
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - T. Beutler
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - M. Zuber
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - A. Bembenek
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - Y. Kitagawa
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - J. Duben
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - C. Codignola
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| | - G. Cserni
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Center, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Kantonsspital Olten, Olten, Switzerland; University Hospital Charité, Berlin, Germany; Keio University School of Medicine, Tokyo, Japan; Chirurgicke Oddeleni Nemocnice Atlas Zlin, Zlin, Czech Republic; Fondazione Poliambulanza, Brescia, Italy; Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary
| |
Collapse
|
12
|
Saha S, Kang E, Beutler T, Hehner C, Bilchik A, Wiese D, Ghanem M, Sehgal R, Patel M. 10 ORAL Prognostic implications of lymphatic mapping in colorectal cancer (CRCa) - a multi-institutional trial. Eur J Surg Oncol 2006. [DOI: 10.1016/s0748-7983(06)70445-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
13
|
Saha S, Sehgal R, Patel M, Wiese D, Bilchik A, Beutler T, Iddings D, Espinosa M, Yee C, Ghanem M. Benefits, limitations and pitfalls of sentinel lymph node (SLN) mapping (M) for colorectal carcinoma (CRCa): A multicenter trial. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3621 Background: Clinical application of SLNM in CRCa patients (pts) is controversial due to the variable results in the literature for its success, skip metastases (mets) and accuracy. Hence prospective data from 5 institutions were analyzed to identify the factors associated with failure and skip mets in CRCa pts undergoing SLNM. Methods: SLNM was performed by peri-tumoral injections of 1–3 ml of 1% lymphazurin subserosally. First 1–4 blue nodes marked as SLNs were examined by 4 sections with H & E and 1 for cytokeratin. Rate of failure and skip mets rate along with age, sex, tumor site, size, grade, T & N stages were analyzed. Results: 549 consecutive CRCa pts underwent SLNM; 453 colon (C) and 96 rectal (R) pts. M: F ratio was 48%: 52% and median age of 72 years. The average no. of LNs was 14.5. SLNM failed in 1% of C and 8% of R pts ( Table ). Of the 8 R failures, 7 had neoadjuvant therapy. No correlation was found between failure, size or T-stage. Overall nodal positivity (+ve) rate was 48%. Of the 466 invasive CRCa pts with successful SLNM, rate of skip mets was 7% in C and 4% in R. Age, sex, grade and neoadjuvant therapy had no correlation with skip mets. Of 28 skip mets pts, 79% had tumors >3cm and 93% had advanced (T3, T4) tumors. Higher skip mets also was found in the transverse colon tumor. The success, accuracy, and sensitivity rates were 98%, 95%, and 88% respectively. Of node +ve pts, 47% had mets found only in the SLNs. SLNM upstaged 35% of C and 36% of R pts with micromets. Conclusions: In CRCa, SLNM is highly successful and accurate in predicting the presence or absence of nodal mets. Submucosal fibrosis of the lymphatics due to neoadjuvant therapy may result in higher failure rates for R pts. Skip mets are higher in transverse C tumors and increase in frequency as the T-stage increases. Pts upstaged by SLNM may benefit from adjuvant chemotherapy. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Saha
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - R. Sehgal
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - M. Patel
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - D. Wiese
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - A. Bilchik
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - T. Beutler
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - D. Iddings
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - M. Espinosa
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - C. Yee
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| | - M. Ghanem
- McLaren Regional Medical Center, Flint, MI; John Wayne Cancer Institute, Santa Monica, CA; Johnny Carson Cancer Center, Norfolk, NE; Genesys Regional Medical Center, Grand Blanc, MI; Easton Hospital, Easton, PA
| |
Collapse
|
14
|
Charriere EA, Beutler T, Caride M, Mordasini P, Orr TE, Zysset PK. Compliance of the L5-S1 spinal unit: a comparative study between an unconstrained and a partially constrained system. Eur Spine J 2006; 15:74-81. [PMID: 15864671 PMCID: PMC3454568 DOI: 10.1007/s00586-004-0807-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2002] [Accepted: 07/30/2004] [Indexed: 10/25/2022]
Abstract
A comparison between an unconstrained and a partially constrained system for in vitro biomechanical testing of the L5-S1 spinal unit was conducted. The objective was to compare the compliance and the coupling of the L5-S1 unit measured with an unconstrained and a partially constrained test for the three major physiological motions of the human spine. Very few studies have compared unconstrained and partially constrained testing systems using the same cadaveric functional spinal units (FSUs). Seven human L5-S1 units were therefore tested on both a pneumatic, unconstrained, and a servohydraulic, partially constrained system. Each FSU was tested along three motions: flexion-extension (FE), lateral bending (LB) and axial rotation (AR). The obtained kinematics on both systems is not equivalent, except for the FE case, where both motions are similar. The directions of coupled motions were similar for both tests, but their magnitudes were smaller in the partially constrained configuration. The use of a partially constrained system to characterize LB and AR of the lumbosacral FSU decreased significantly the measured stiffness of the segment. The unconstrained system is today's "gold standard" for the characterization of FSUs. The selected partially constrained method seems also to be an appropriate way to characterize FSUs for specific applications. Care should be taken using the latter method when the coupled motions are important.
Collapse
Affiliation(s)
- E A Charriere
- Mechanical Engineering Department, Laboratory of Applied Mechanics and Reliability Analysis, Swiss Federal Institute of Technology, Lausanne, Switzerland.
| | | | | | | | | | | |
Collapse
|
15
|
Saha S, Beutler T, Dan AG, Sehgal R, Puthillath A, Wiese D, Ng P, Peram V, Arora M, Singh T. Impact of sentinel lymph node (SLN) mapping (M) on nodal metastasis (mets) and recurrence in colon cancer (Cca) compared with conventional surgery (CS). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Saha
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - T. Beutler
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - A. G. Dan
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - R. Sehgal
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - A. Puthillath
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - D. Wiese
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - P. Ng
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - V. Peram
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - M. Arora
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| | - T. Singh
- McLaren Regional Medcl Ctr, Flint, MI; Faith Regional Medcl Ctr, Norfolk, NE; Michigan State Univ, East Lansing, MI
| |
Collapse
|
16
|
Abstract
The mobile SIREMOBIL Iso-C(3D) C-arm (Siemens, Erlangen, Germany) is the first device permitting intraoperative, three-dimensional representation of bone structures. A high-resolution, isotropic 3D data cube in the isocenter with sides of approximately 12 cm is calculated simultaneously. The SIREMOBIL Iso-C(3D) is linked to the navigation system. This makes it possible to transfer the generated 3D data directly to the linked navigation system without the need for surgeon-dependent registration. In this prospective clinical trial, we evaluated the accuracy of pedicle screw placement using this device. In 61 patients, a total of 302 pedicle screws were placed. Only in five cases (1.7%) were misplacements of > or =2 mm shown in postoperative control CT. The average fluoroscopy time was 1.28+/-0.56 min, and the average operative duration was 103.26+/-23.3 min. There were no postoperative neurological complications in any of the 30 patients. From these data, we conclude that Iso-C(3D) navigation is a very accurate method for the placement of pedicle screws.
Collapse
Affiliation(s)
- P A Grützner
- Berufsgenossenschaftliche Unfallklinik Ludwigshafen, Klinik für Unfall- und Wiederherstellungschirurgie an der Universität Heidelberg
| | | | | | | | | | | |
Collapse
|
17
|
Dan A, Saha S, Wiese D, Bilchik A, Nolff M, Beutler T, AlSamkari R, Barber K, Branigan T, Kaushal S. Upstaging of early colon cancer (T1 & T2) by sentinel lymph node (SLN) mapping. Ann Surg Oncol 2004. [DOI: 10.1007/bf02524155] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Saha S, Wiese D, Badin J, Beutler T, Nora D, Ganatra BK, Desai D, Kaushal S, Nagaraju M, Arora M, Singh T. Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging. Ann Surg Oncol 2000; 7:120-4. [PMID: 10761790 DOI: 10.1007/s10434-000-0120-z] [Citation(s) in RCA: 191] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Sentinel lymph node (SLN) mapping for melanoma and breast cancer has greatly enhanced the identification of micrometastases in many patients, thereby upstaging a subset of these patients. The purpose of this study was to see if SLN mapping technique could be used to identify SLNs in colorectal cancer and to assess its impact on pathological staging and treatment. METHODS At the time of surgery, 1 ml of Lymphazurin 1% was injected subserosally around the tumor without injecting into the lumen. The first to fourth blue nodes identified were considered the SLNs, which have the highest probability to contain metastases. A standard oncological resection of the bowel was then performed. Multilevel microsections of the SLNs, including a detailed pathological examination of the entire specimen, was performed. RESULTS SLN was successfully identified in 85 (98.8%) of 86 patients. In 85 patients, there were 1,367 (16 per patient) lymph nodes examined, of which 140 (1.6 per patient) were identified as SLNs. In 53 (95%) of 56, of whom the SLNs were without metastases (negative), all other non-SLNs also were negative. In 29 (34% of 85) patients, SLNs were positive for metastases; in 14 of the 29 patients, other non-SLNs also were positive in addition to the SLNs. In the other 15 of the 29 patients (18% of 85 patients), SLNs were the only site of metastases, and all other non-SLNs were negative. In 7 patients (8.2% of 85 patients), micrometastases were identified only in 1 or 2 of the 10 sections of a single SLN. In five of seven patients, such micrometastases were detected by hematoxylin and eosin staining and immunohistochemistry; in the other two patients, it was detected only by immunohistochemistry. In patients with negative SLNs, the rate of occurrence of micrometastases in non-SLNs was 5 (0.4%) of 1,184 lymph nodes. CONCLUSIONS SLN mapping can be performed easily in colorectal cancer patients, with an accuracy of more than 95%. The identification of submicroscopic lymph node metastases by this technique may have upstaged these patients (18%) from stage I/II to stage III disease, who may then benefit from further adjuvant chemotherapy.
Collapse
Affiliation(s)
- S Saha
- Department of Anatomy, Michigan State University, McLaren Regional Medical Center, Flint, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Vaterlaus A, Beutler T, Guarisco D, Lutz M, Meier F. Spin-lattice relaxation in ferromagnets studied by time-resolved spin-polarized photoemission. Phys Rev B Condens Matter 1992; 46:5280-5286. [PMID: 10004305 DOI: 10.1103/physrevb.46.5280] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
20
|
Vaterlaus A, Beutler T, Meier F. Spin-lattice relaxation time of ferromagnetic gadolinium determined with time-resolved spin-polarized photoemission. Phys Rev Lett 1991; 67:3314-3317. [PMID: 10044701 DOI: 10.1103/physrevlett.67.3314] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|